Cantargia AB (CANTA) NPV

Sell:1.74 SEKBuy:1.75 SEK0.03 SEK (1.52%)

Prices delayed by at least 15 minutes
Sell:1.74 SEK
Buy:1.75 SEK
Change:0.03 SEK (1.52%)
Deal now
Prices delayed by at least 15 minutes
Sell:1.74 SEK
Buy:1.75 SEK
Change:0.03 SEK (1.52%)
Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Cantargia AB is a Sweden-based company engaged in development of antibody therapeutics for the treatment of leukemia. The Company is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.

Key people

Goeran Forsberg
Chief Executive Officer
Patrik Renblad
Chief Financial Officer
Susanne Lagerlund
Vice President - Regulatory Affairs
David Liberg
Vice President - Research
Nedjad Losic
Vice President - Biometrics
Peter Jull Madsen
Vice President - CMC
Lars Thorsson
Vice President - Clinical Development
Roger Belusa
Chief Medical Officer
Ton Berkien
Chief Business Officer
Dominique Tersago
Chief Medical Officer
Magnus Modee Persson
Independent Chairman of the Board
Flavia Borellini
Independent Director
Patricia Delaite
Independent Director
Thoas Fioretos
Independent Director
Karin Leandersson
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Sweden
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    SE0006371126
  • Market cap
    SEK 441.78m
  • Employees
    21
  • Shares in issue
    183.69m
  • Exchange
    Stockholm Stock Exchange
  • Index
    SX All Share PI Market Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.